Top

Category: Industry


Industry, Vaccines

WHO announces recommended 2023 flu vaccines for southern hemisphere

September 27, 2022

Via: PMLiVE

The recommendation is based on the advice of a group of experts from WHO Collaborating Centres (CC) and WHO Essential Regulatory Laboratories that analyse virus surveillance data generated by the WHO Global Influenza Surveillance and Response System, a global network […]


Industry, Vaccines

Pfizer and BioNTech seek FDA authorisation for COVID-19 booster for children

September 27, 2022

Via: PMLiVE

The bivalent vaccine contains mRNA encoding the original SARS-CoV-2 spike protein – present in the original Pfizer/BioNTech COVID-19 vaccine – together with mRNA encoding the spike protein of the Omicron BA.4/BA.5 variant. A 30µg booster dose has already been granted […]


Biotech, Industry

Prime Medicine becomes the next high-profile biotech to test the IPO waters

September 26, 2022

Via: Biopharma Dive

Prime’s filing represents a key test for biotech initial public offerings, which are showing some early signs of life after a prolonged slowdown. Twelve days ago, autoimmune drug developer Third Harmonic Bio provided the sector with a lift. By raising […]


Cell and Gene Therapy, Clinical Trials, Industry, Research and Development

Pfizer, Sangamo resume haemophilia gene therapy trial

September 26, 2022

Via: Pharmaphorum

The phase 3 AFFINE trial was paused voluntarily by the two partners almost a year ago, and subsequently placed on hold by the FDA, after patients treated with the therapy produced higher than expected levels of Factor VIII – the […]


Cell and Gene Therapy, Clinical Trials, Industry, Research and Development

Pfizer, Sangamo set to resume gene therapy study after safety delay

September 23, 2022

Via: Biopharma Dive

Pfizer and Sangamo Therapeutics will soon resume a Phase 3 trial of their gene therapy for the blood disorder hemophilia A, nearly a year after safety concerns forced its suspension. Specifically, the companies said Thursday evening they plan to resume […]


Cell and Gene Therapy, Industry, Mergers and Acquisitions

GenScript and Avectas Partner on Next-Generation Cell Therapies

September 22, 2022

Via: GEN

GenScript and Avectas agreed to partner to develop an improved non-viral cell therapy manufacturing process. By combining Avectas’ cell engineering technology with GenScript’s expertise in synthetic long oligo production, the partnership aims to demonstrate a novel and efficient solution for […]


Industry, Vaccines

Reconfiguring COVID and influenza vaccines for long-term effectiveness

September 22, 2022

Via: Pharmaphorum

Alexandre Le Vert, CEO and co-founder of Osivax, discusses the company’s breakthrough vaccine technology, oligoDOM, and how it’s driving the development of new influenza and SARS-CoV-2 vaccines that attack T-cells, providing a long-lasting effect. Currently, available vaccines for influenza and […]


Cell and Gene Therapy, Industry, Mergers and Acquisitions

GenScript and Avectas link up to improve non-viral cell therapy processes

September 20, 2022

Via: Pharma Times

GenScript – the life-sciences research tools and services provider – and Avectas, a cell engineering technology company, are partnering to develop an improved non-viral cell therapy manufacturing process. The two companies are focusing on new methods for developing cell therapies […]


Industry, Vaccines

Keeping the pandemic at bay with needle-free vaccine delivery

September 20, 2022

Via: Pharmaphorum

Vaccines have transitioned from being a largely unloved area of the industry, with multiple big pharma companies divesting their vaccine divisions, to the biggest revenue drivers seen in recent years. This all comes down to the impact of the pandemic. […]


Cell and Gene Therapy, Industry

Back-to-back gene therapy approvals give Bluebird shot at survival

September 19, 2022

Via: Biopharma Dive

Until this August, just two gene therapies for inherited diseases were available in the U.S. Now, in the span of one month, that count has doubled, with the Food and Drug Administration approving new treatments for a rare blood condition […]


Biotech, Industry

Biotechnology Gets $2 Billion Boost from the White House

September 15, 2022

Via: GEN

This week has been one of the most exciting that the biotechnology community has seen for some time. Plans that have been in the making for a decade are finally being brought to fruition by actions taken by the Biden […]


Industry, Vaccines

Pfizer, BioNTech’s mRNA flu vaccine starts phase 3 testing

September 15, 2022

Via: Pharmaphorum

The first patients have been dosed in a phase 3 trial of an mRNA-based seasonal influenza vaccine developed by Pfizer and BioNTech, which may offer quicker production and greater efficacy than shots made using traditional cell culture or recombinant techniques. […]


Clinical Trials, Industry, Research and Development, Vaccines

Pfizer reports success in trial of all-in-one meningitis vaccine

September 15, 2022

Via: Biopharma Dive

An experimental meningococcal vaccine that protects against five strains of the bacteria succeeded in a Phase 3 clinical trial, Pfizer said Thursday, potentially offering an alternative to existing shots that cover fewer variants and require more doses. By the end […]


Cell and Gene Therapy, Industry

SparingVision raises €75m for eye disease gene therapies

September 14, 2022

Via: Pharmaphorum

The French biotech said the cash injection – which follows a €45 million Series A in 2020 – will also help it bring forward the first development candidate in a collaboration signed with gene-editing specialist Intellia Therapeutics last year, currently […]


Cell and Gene Therapy, Industry

Ori Biotech Partners with the Cell Therapy Manufacturing Center to Accelerate Cell Therapy Delivery

September 13, 2022

Via: Contract Pharma

Ori Biotech, a leader in cell and gene therapy (CGT) manufacturing technologies, and the Cell Therapy Manufacturing Center (CTMC), a joint venture between National Resilience Inc. and MD Anderson Cancer Center, have entered a collaborative partnership to develop industrial manufacturing […]


Industry, Vaccines

Pfizer’s Omicron BA.4/BA.5 vaccine recommended by CHMP

September 12, 2022

Via: Pharmaphorum

The European Commission is now expecting to make a final decision on the updated version of the two drugmakers’ original Comirnaty shot within the next couple of weeks. The EMA said the decision by the CHMP will “further extend the […]


Industry, Pharma

Pharma’s climate change vulnerability and opportunity

September 9, 2022

Via: Pharmaphorum

Pharma’s reliance on global supply chains and its need for vast quantities of water make it particularly vulnerable to climate change. But preparing to adapt to the phenomenon presents an opportunity as well as a challenge. Rising global temperatures will, […]


Cell and Gene Therapy, Industry

Potential Gene Therapy Developed for Childhood Blinding Disease

September 9, 2022

Via: GEN

Researchers at the National Eye Institute (NEI), part of the National Institutes of Health, have developed a gene therapy that rescues cilia defects in retinal cells affected by a type of Leber congenital amaurosis (LCA), a disease that causes blindness […]


Industry, Vaccines

New malaria vaccine shows high efficacy, yields high hopes

September 8, 2022

Via: Pharmaphorum

Hopes were already running high for the R21/Matrix-M vaccine, after it showed 77% protective efficacy over 12 months in a phase 2b trial involving young west African children – meeting the World Health Organization’s efficacy goal of 75% – after […]


Industry, Vaccines

First Needle-Free COVID Vaccines Get OK in India, China

September 7, 2022

Via: Drugs.com

While researchers explore the possibilities of COVID-19 vaccines that don’t require an injection, public health officials in India and China have already each approved new needle-free versions for their citizens. In India, regulators on Tuesday approved a nasal vaccine developed […]